A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
In brief
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Key facts
- Study ID
- NCT06778863
- Run by
- Clasp Therapeutics, Inc.
- People needed
- 90
- Starts
- 2025-02-28
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-02-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth Research Institute — Scottsdale, Arizona, United States (enrolling)
- The University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
- USC - Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- University of California Davis Comprehensive Cancer Center — Sacramento, California, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
- The University of Chicago Comprehensive Cancer Center — Chicago, Illinois, United States (enrolling)
- University of Kentucky Markey Cancer Center — Lexington, Kentucky, United States (enrolling)
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States (enrolling)
- Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- NYU Langone Health — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
- Thomas Jefferson University, Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee, United States (enrolling)
- Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)
- Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
- Baylor University Medical Center — Dallas, Texas, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.